Author | Jesus G. Berdeja, MD | OncLive

Author | Jesus G. Berdeja, MD

Articles

Dr. Berdeja on Dosing JNJ-4528 in Relapsed/Refractory Multiple Myeloma

July 08, 2020

Video

Jesus G. Berdeja, MD, discusses the dosing of the investigational CAR T-cell product JNJ-4528 in patients with ​relapsed/refractory multiple myeloma.

Dr. Berdeja on Next Steps With JNJ-4528 in Relapsed/Refractory Myeloma

June 25, 2020

Video

Jesus G. Berdeja, MD, discusses next steps for the phase 2 CARTITUDE-1 study with JNJ-4528 in relapsed/refractory myeloma.

Dr. Berdeja on Updated CARTITUDE-1 Results With JNJ-4258 in Multiple Myeloma

June 15, 2020

Video

Jesus G. Berdeja, MD, discusses updated safety results from the ongoing phase 1b/2 CARTITUDE-1 trial (NCT03548207) with the CAR T-cell therapy JNJ-4528 in multiple myeloma.

Dr. Berdeja on FDA Approval of Frontline Daratumumab Plus VMP in Multiple Myeloma

May 08, 2018

Video

Jesus G. Berdeja, MD, director of Myeloma Research, principal investigator, Sarah Cannon Research Institute, discusses the FDA approval of frontline daratumumab (Darzalex) in combination with bortezomib (Velcade), melphalan, and prednisone (VMP) for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT).

x